Metacortil-Lite Cream is a topical formulation combining Hydroquinone (2% w/w), Mometasone (0.1% w/w), and Tretinoin (0.025% w/w), designed for the treatment of hyperpigmentation disorders and inflammatory dermatoses. Hydroquinone acts as a skin-lightening agent by inhibiting tyrosinase, thereby reducing melanin synthesis and effectively diminishing dark spots, melasma, and other pigmentary abnormalities. Mometasone, a potent corticosteroid, provides anti-inflammatory, antipruritic, and vasoconstrictive effects, helping to reduce erythema, swelling, and irritation associated with inflammatory skin conditions. Tretinoin, a retinoid derivative, promotes epidermal cell turnover and enhances skin renewal, which aids in improving texture and reducing fine pigmentation. The synergistic combination of these active ingredients in Metacortil-Lite Cream offers a comprehensive approach to managing hyperpigmentation while controlling inflammation and promoting skin regeneration. It is indicated for short-term use under medical supervision due to the potential for corticosteroid-related side effects and skin irritation from tretinoin. Patients should avoid excessive sun exposure and use sunscreen during treatment to prevent further pigmentation. This product is contraindicated in individuals with hypersensitivity to any component and should be used cautiously in pregnant or lactating women.